2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Yahoo3 hours agoINCY
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
YahooyesterdayINCY
Incyte Corporation: Why Jakafi Is No Longer The Real Story Here
Incyte is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. See why INCY stock is a Buy.
SeekingAlpha2 days agoINCY
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del., September 01, 2026--Incyte to Present at Upcoming Investor Conferences
Yahoo3 days agoINCY
Incyte (INCY) Just Moved, So What Is Drawing Attention Now?
Incyte (INCY) is back in focus following renewed attention on upcoming ESMO data for its KRAS G12D inhibitor, known as 734, which is being studied in combination with chemotherapy for pancreatic ductal adenocarcinoma. The renewed focus on Incyte comes after a strong run in the share price, with the latest close at US$124.37 and a 90 day share price return of 30.11%. That move sits within a broader trend where the year to date share price return is 22.63%, while total shareholder return over 1...
Yahoo5 days agoINCY
Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734
Incyte (NasdaqGS: INCY) is drawing attention as its KRAS G12D inhibitor '734 heads into new data presentations at ESMO, focused on pancreatic ductal adenocarcinoma. The upcoming ESMO readout is expected to support ongoing Phase 3 trials of '734 in pancreatic cancer, a disease area with high unmet medical need. Interest is heightened after a competitor recently received FDA approval for a therapy targeting a similar pathway in oncology. This spotlight on Incyte shows how much investor...
Yahoo5 days agoINCY
Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?
Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal […]
Yahoo6 days agoINCY
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?
uniQure (QURE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo7 days agoINCY
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adult
Yahoo7 days agoINCY
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.
SeekingAlpha9 days agoINCY
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
Yahoo11 days agoINCY
Prelude Therapeutics: A Prognosis After Year-Long Rally
Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.
SeekingAlpha12 days agoINCY
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
SeekingAlpha13 days agoINCY
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $25.75 billion.
Benzinga14 days agoINCY
Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.
Benzinga15 days agoINCY
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
Benzinga15 days agoINCY
Silence Therapeutics: Making Some Recent Noise
Silence Therapeutics rises on trial results and funding updates; Read on to see Divesiranâs outlook vs. Takedaâs rusfertide competition and analyst views.
SeekingAlpha16 days agoINCY
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.
Benzinga18 days agoINCY
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup
Incyte (INCY) shows strong growth momentum with a clean technical setup, combining high earnings growth, positive ratings, and a breakout opportunity.
ChartMill18 days agoINCY
IHF: Healthcare Dashboard For August
Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.
SeekingAlpha19 days agoINCY
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]
Yahoo21 days agoINCY
Incyte Sales Growth Drives Share Price Gains
Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.
Yahoo23 days agoINCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del., August 07, 2026--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo27 days agoINCY
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Yahoo29 days agoINCY
REGN or INCY: Which Is the Better Value Stock Right Now?
REGN vs. INCY: Which Stock Is the Better Value Option?
Yahoolast monthINCY
Mizuho Maintains Outperform on Incyte, Raises Price Target to $137
Mizuho analyst Salim Syed maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $121 to $137.
Benzingalast monthINCY
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
AbbVie Inc. stock fell 6.2% after a 52-week high despite strong Q2 earnings; Rinvoq and Elahere sales surged. Click for this ABBV earnings udpate.
SeekingAlphalast monthINCY
Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65, BTIG boosted SNOW's target to $340, and JP Morgan upgraded LYB to Overweight.
Benzingalast monthINCY
